There is an emergency need for early ambulatory treatment of Coronavirus
Disease 2019 (COVID-19) in acutely ill patients in an attempt to reduce disease
progression and the risks of hospitalization and death. Such management should
be applied in high-risk patients age
Cite this article
388
Downloads
30
Citations
2330
Views
Announcements
Open Access
Original Research
Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection
Brian C. Procter1, Casey Ross1, Vanessa Pickard1, Erica Smith1, Cortney Hanson1, Peter A. McCullough2,3,4,*
Show Less
1
McKinney Family Medicine, McKinney, 75070, TX, USA
2
Baylor University Medical Center, Dallas, 75226, TX, USA
3
Baylor Heart and Vascular Institute, Dallas, 75226, TX, USA
4
Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, 75226, TX, USA
*Correspondence: peteramccullough@gmail.com (Peter A. McCullough)
Rev. Cardiovasc. Med. 2020, 21(4), 611–614;
https://doi.org/10.31083/j.rcm.2020.04.260
Submitted: 26 November 2020 | Revised: 9 December 2020 | Accepted: 14 December 2020 | Published: 30 December 2020
Copyright: © 2020 Procter et al. Published by IMR Press.
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract
Keywords
SARS-CoV-2
COVID-19
multidrug
hospitalization
mortality
ambulatory
antiviral
zinc
hydroxychloroquine
ivermectin
doxycycline
azithromycin
vitamin
corticosteroid
Figures
Fig. 1.